{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:17Z","timestamp":1786119257933,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/jcp.0b013e31819a8dbe","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T08:53:34Z","timestamp":1242896014000},"page":"165-169","source":"Crossref","is-referenced-by-count":89,"title":["Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients"],"prefix":"10.1097","volume":"29","author":[{"given":"David C.","family":"Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoduo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina P.","family":"Borba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Boxill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Freudenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Cather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Eden","family":"Evins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 10","key":"R1-9-20210128","first-page":"13","article-title":"Safety of olanzapine.","volume":"58","author":"Beasley","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4088\/JCP.v60n1109","article-title":"Olanzapine increases weight and serum triglyceride levels.","volume":"60","author":"Osser","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004714-199906000-00014","article-title":"Olanzapine: weight gain and therapeutic efficacy.","volume":"19","author":"Gupta","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study.","volume":"157","author":"Henderson","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.","volume":"59","author":"Koro","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","article-title":"Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.","volume":"170","author":"Melkersson","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0920-9964(02)00305-5","article-title":"Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.","volume":"60","author":"Atmaca","year":"2003","journal-title":"Schizophr Res"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1176\/ajp.156.9.1471-a","article-title":"Olanzapine-induced elevation of plasma triglyceride levels.","volume":"156","author":"Sheitman","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4088\/JCP.v67n0513","article-title":"Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"67","author":"Henderson","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-2006-931545","article-title":"Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.","volume":"39","author":"Luebbe","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4088\/JCP.v68n0308","article-title":"Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.","volume":"68","author":"Spurling","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.","volume":"23","author":"Weiden","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1176\/appi.ps.52.7.967","article-title":"A program for treating olanzapine-related weight gain.","volume":"52","author":"Ball","year":"2001","journal-title":"Psychiatr Serv"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4088\/JCP.v65n0404","article-title":"Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.","volume":"65","author":"Menza","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/070674370304800910","article-title":"Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.","volume":"48","author":"Archie","year":"2003","journal-title":"Can J Psychiatry"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.160.2.297","article-title":"Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.","volume":"160","author":"Poyurovsky","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1176\/appi.ajp.159.6.1058","article-title":"Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.","volume":"159","author":"Poyurovsky","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","article-title":"A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.","volume":"162","author":"Henderson","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2004.03.005","article-title":"Amantadine for weight gain associated with olanzapine treatment.","volume":"15","author":"Deberdt","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4088\/JCP.v63n1116a","article-title":"Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia.","volume":"63","author":"Levy","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.","volume":"165","author":"Wu","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1176\/appi.ajp.159.4.655","article-title":"Metformin for weight loss in pediatric patients taking psychotropic drugs.","volume":"159","author":"Morrison","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881106068289","article-title":"Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?","volume":"21","author":"Karunakaran","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archpsyc.1992.01820080032005","article-title":"The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description.","volume":"49","author":"Spitzer","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R31-9-20210128","first-page":"343","article-title":"SAFETEE: a technique for the systematic assessment of side effects in clinical trials.","volume":"22","author":"Levine","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00005768-199805000-00021","article-title":"Calibration of the Computer Science and Applications, Inc. accelerometer.","volume":"30","author":"Freedson","year":"1998","journal-title":"Med Sci Sports Exerc"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1097\/00005768-200009001-00003","article-title":"Estimation of energy expenditure using CSA accelerometers at hip and wrist sites.","volume":"32","author":"Swartz","year":"2000","journal-title":"Med Sci Sports Exerc"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-8981(87)90188-4","article-title":"Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions.","volume":"166","author":"McNamara","year":"1987","journal-title":"Clin Chim Acta"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cll.2006.07.004","article-title":"Cholesterol profile measurement by vertical auto profile method.","volume":"26","author":"Kulkarni","year":"2006","journal-title":"Clin Lab Med"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1210\/jcem-54-2-254","article-title":"Relationship of body fat distribution to metabolic complications of obesity.","volume":"54","author":"Kissebah","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2337\/diacare.19.4.387","article-title":"Insulin resistance in the pathogenesis of dyslipidemia.","volume":"19","author":"Garg","year":"1996","journal-title":"Diabetes Care"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2337\/diab.43.3.411","article-title":"Isolated low HDL cholesterol. An insulin-resistant state.","volume":"43","author":"Karhapaa","year":"1994","journal-title":"Diabetes"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/edrv.23.2.0461","article-title":"Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.","volume":"23","author":"Lewis","year":"2002","journal-title":"Endocr Rev"},{"key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"suppl 7","key":"R41-9-20210128","first-page":"4","article-title":"The pharmacology of weight gain with antipsychotics.","volume":"62","author":"Casey","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3956(03)00018-9","article-title":"Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.","volume":"37","author":"Zimmermann","year":"2003","journal-title":"J Psychiatr Res"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050952","article-title":"Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice.","volume":"143","author":"Vickers","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2174\/1568026033452249","article-title":"5-HT2C receptor agonists as potential drugs for the treatment of obesity.","volume":"3","author":"Bickerdike","year":"2003","journal-title":"Curr Top Med Chem"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-200904000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:54:40Z","timestamp":1786038880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200904000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31819a8dbe","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}